# **Special Issue**

# Advancements in Clinical Applications of Immune Checkpoint Inhibitors

### Message from the Guest Editors

It has been more than ten years since the clinical use of immune checkpoint inhibitors (ICIs), and we are still trying to utilize them more effectively. This Special Issue aims to compile a collection of articles that highlight the latest advancements in the clinical research of immune checkpoint inhibitors, including but not limited to the following:

- Clinical trials evaluating the efficacy and safety of immune checkpoint inhibitors in different cancer types.
- Combination therapies involving immune checkpoint inhibitors.
- Management of adverse events related to immune checkpoint inhibitors.
- Biomarkers related to immune checkpoint inhibitor therapy.
- Timing to stop ICIs.

We invite the submission of original research articles, reviews, and case reports in this field.

#### **Guest Editors**

Dr. Yugo Ashino

Department of Respiratory Medicine, Sendai City Hospital, Sendai 982-8502, Miyagi, Japan

Dr. Ichiro Onoyama

Department of Obstetrics and Gynecology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

### Deadline for manuscript submissions

closed (30 November 2024)



# Reports

an Open Access Journal by MDPI

Impact Factor 0.6
Indexed in PubMed



mdpi.com/si/200301

Reports
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
reports@mdpi.com

mdpi.com/journal/ reports





# Reports

an Open Access Journal by MDPI

Impact Factor 0.6 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

### **Editor-in-Chief**

#### Prof. Dr. Toshio Hattori

- 1. Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka 420-0881, Shizuoka, Japan
- 2. International Research Institute of Disaster Science, Tohoku University, Sendai 980-8577, Miyagi, Japan

#### **Author Benefits**

#### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### **High Visibility:**

indexed within ESCI (Web of Science), FSTA, and other databases.

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.7 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

